Premium
IC‐P‐195: QUANTIFICATION OF WHITE MATTER CELLULARITY IN PRECLINICAL AND EARLY SYMPTOMATIC ALZHEIMER DISEASE USING NEURO‐IMMNUE IMAGING
Author(s) -
Wang Qing,
Wang Yong,
Shimony Joshua S.,
Liu Jingxia,
Fagan Anne M.,
Cairns Nigel J.,
Ances Beau M.,
Morris John C.,
Benzinger Tammie L.S.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2262
Subject(s) - biomarker , white matter , neuroinflammation , corpus callosum , fractional anisotropy , imaging biomarker , medicine , diffusion mri , cerebrospinal fluid , pathology , dementia , inflammation , disease , oncology , magnetic resonance imaging , biology , radiology , biochemistry
background field calculated by local polynomial approximation. Region of interest analysis was performed with an automated anatomical labeling template for 120 regions. Relative susceptibility values to the frontal white matter were compared between the AD and CN groups with analysis of covariance, in which age was used for covariance. Results:In the conventional method, significant increases were observed in susceptibility in AD patients compared with that in CN subjects in only five regions (Fig. 1), namely the right putamen (p 1⁄4 0.003), left lateral orbitofrontal cortex (p 1⁄4 0.003), right transverse temporal gyrus (p1⁄4 0.024), right amygdala (p 1⁄4 0.028), and left putamen (p 1⁄4 0.042). Contrastingly, 21 regions (Fig. 2) showed significant increases in the susceptibility in AD patients with the novel method, including the left anterior orbitofrontal cortex (p 1⁄4 0.002), left lateral orbitofrontal cortex (p 1⁄4 0.004), left inferior occipital gyrus (p 1⁄4 0.007), right parahippocampal gyrus (p 1⁄4 0.015), and right medial orbital gyrus (p 1⁄4 0.017). Conclusions: Using the newly developed QSM analysis method, more regions show a significantly higher susceptibility in AD patients. Thus, this method may facilitate an early diagnosis of AD and other neurodegenerative diseases.